Bupropion Toxicity Presenting As Alcohol Withdrawal Syndrome: A Case Report
Abstract
Bupropion toxicity can present as neurologic and autonomic manifestations that closely resemble alcohol withdrawal syndrome, a diagnostic challenge that becomes compounded when patients are unable to provide reliable histories and when confirmatory toxicology results are delayed. We present the case of a 55-year-old male who presented with agitation, encephalopathy, auditory and visual hallucinations, hypertension, tremors, and suspected seizure activity. Based on his substance use history and clinical presentation, he was managed as alcohol withdrawal using symptom-triggered benzodiazepines per the Clinical Institute Withdrawal Assessment for Alcohol-Revised protocol. Serum ethanol level and urine toxicology screen were negative on admission, and he improved with supportive care and benzodiazepine therapy in the intensive care unit. Serum toxicology results returned after discharge and revealed markedly elevated bupropion and hydroxybupropion concentrations, establishing clinically significant bupropion toxicity as the true etiology. While bupropion toxicity mimicking alcohol withdrawal has been described, cases in which the diagnosis was established only after discharge, when quantitative metabolite assays returned, remain rare. This case illustrates how convincingly bupropion toxicity can masquerade as alcohol withdrawal syndrome, and how antidepressant toxicity belongs on the differential in any patient presenting with unexplained encephalopathy and autonomic…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.